Mindful Health Solutions Ketamine Infusion Therapy Clinic
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Oakland, CA
Oakland has a particular chelation demand profile driven by its industrial history. Legacy lead exposure from pre-1978 housing stock in West Oakland and Fruitvale, plus Port of Oakland diesel emissions and documented soil contamination near former smelter sites, means pediatric lead screening and adult heavy metal workups come up more often here than in surrounding Bay Area cities. The Alameda County Public Health Department flags elevated blood lead levels each year and routes confirmed poisoning through Childrens Hospital Oakland and Kaiser Oakland.
Outside confirmed poisoning, 3 integrative and naturopathic clinics in Oakland offer chelation on a cash-pay basis, typically MDs or DOs with ACAM training and naturopathic doctors operating within California scope-of-practice rules. Common agents include calcium disodium EDTA, DMPS, DMSA, and deferoxamine. Protocols range from 10-session provoked detox courses to longer 30-session TACT-style cardiovascular protocols. Regenerated.com does not recommend chelation for autism or cardiovascular disease outside clinical trials. The FDA has approved specific agents for specific heavy metal poisoning diagnoses only, and off-label use has caused fatal hypocalcemia when administered without monitoring.
Regulatory context
The FDA has approved a narrow set of chelating agents for specific heavy metal toxicities. Calcium disodium edetate (CaNa2EDTA, Versenate) is approved for symptomatic lead poisoning, succimer (Chemet, DMSA) for pediatric lead poisoning at blood lead levels above 45 mcg/dL, deferoxamine (Desferal) and deferasirox (Exjade) for chronic iron overload, and dimercaprol (BAL) for arsenic, gold, and acute lead poisoning. Use of EDTA chelation for cardiovascular disease was studied in the NIH-funded TACT trial (2013) with controversial findings and remains not FDA-approved for that indication. Chelation for autism spectrum disorder is not evidence-based and has been linked to pediatric deaths. The FDA issued a 2010 sweep of warning letters to compounders marketing OTC chelation products with unapproved disease claims.
The Medical Board of California has disciplined physicians for marketing chelation as a treatment for autism, atherosclerosis, and Alzheimer's disease without adequate informed consent or evidence base. California Department of Public Health has investigated clinics for unsanitary IV practices. The Pittsburgh 2005 pediatric autism chelation death prompted California medical board guidance reinforcing that the wrong EDTA salt (Na2EDTA versus CaNa2EDTA) can be fatal. Compounded DMPS distribution has drawn scrutiny under California pharmacy law.